A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
复制标题
DOI：
10.7150/ijbs.15438
复制
发表时间：
2016
影响因子：
9.2
通讯作者：
Ren J
中科院分区：
文献类型：
--
作者：
Li Y;Wang J;Ma X;Tan L;Yan Y;Xue C;Hui B;Liu R;Ma H;Ren J
新辅助放化疗已成为局部晚期直肠癌的标准治疗方法。新辅助放化疗不仅能缩小肿瘤体积，降低复发率，而且能提高肿瘤切除率和肛门留存率，副作用小。与术前化疗相比，术前放化疗可进一步降低局部复发率和提前期。新辅助放化疗对中低位直肠癌的疗效优于高位直肠癌。新辅助放化疗的患者选择和放疗方式的选择有待进一步完善。新辅助放化疗的不同治疗反应影响手术技术的类型，因此需要引起更多的关注。此外，术前准确分期、选择合适的新辅助放化疗方法、预测术前放疗敏感性等问题尚待解决。
Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and downstage. Middle and low rectal cancers can benefit more from neoadjuvant chemradiotherapy than high rectal cancer. It needs to refine the selection of appropriate patients and irradiation modes for neoadjuvant chemoradiotherapy. Different therapeutic reactions to neoadjuvant chemoradiotherapy affect the type of surgical techniques, hence calling for the need of much attention. Furthermore, many problems such as accurate staging before surgery, selection of suitable neoadjuvant chemoradiotherapy method, and sensitivity prediction to preoperative radiotherapy need to be well settled.